Saxenda vs Wegovy

Saxenda (liraglutide 3 mg) and Wegovy (semaglutide 2.4 mg) are both GLP-1 receptor agonists approved by the FDA for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity. Saxenda, approved in 2014, represents the first generation of GLP-1 therapies indicated specifically for weight loss. Wegovy, approved in 2021, is a newer-generation option within the same drug class. Both are manufactured by Novo Nordisk and require subcutaneous injection, but they differ significantly in dosing frequency, observed weight-loss efficacy, and additional approved indications.

One of the most notable practical differences is dosing schedule. Saxenda requires a once-daily injection, while Wegovy is administered once weekly. In clinical trials, the efficacy gap has been substantial. In the SCALE Obesity and Prediabetes trial, Saxenda demonstrated approximately 8% mean body weight loss over 56 weeks. In the STEP 1 trial, Wegovy showed approximately 16.9% mean body weight loss over 68 weeks. The STEP 8 trial directly compared semaglutide 2.4 mg (Wegovy's dose) with liraglutide 3 mg (Saxenda's dose) and found that semaglutide produced significantly greater weight reduction. Additionally, Wegovy has received FDA approval for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, based on results from the SELECT trial. Saxenda does not carry this cardiovascular indication.

Both medications share common side effects typical of the GLP-1 class, including nausea, vomiting, diarrhea, constipation, and abdominal pain, particularly during dose titration. Despite Wegovy's greater efficacy in clinical trials and its weekly dosing convenience, Saxenda may still be a relevant option in certain clinical scenarios. Depending on the patient's insurance formulary, Saxenda may have broader coverage or lower out-of-pocket cost. In some markets, Saxenda has also had more consistent supply availability. The choice between these medications should be made in consultation with a healthcare provider, who can consider the patient's individual health profile, treatment goals, insurance coverage, and medication availability.